These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 16611151)
1. The management of phosphodiesterase-5 (PDE5) inhibitor failure. Lau DH; Kommu S; Mumtaz FH; Morgan RJ; Thompson CS; Mikhailidis DP Curr Vasc Pharmacol; 2006 Apr; 4(2):89-93. PubMed ID: 16611151 [TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Corbin JD; Francis SH; Webb DJ Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329 [TBL] [Abstract][Full Text] [Related]
3. Future options for combination therapy in the management of erectile dysfunction in older men. Sommer F; Engelmann U Drugs Aging; 2004; 21(9):555-64. PubMed ID: 15260511 [TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 mechanisms and therapeutic applications. Burnett AL Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563 [TBL] [Abstract][Full Text] [Related]
5. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Kloner RA Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566 [TBL] [Abstract][Full Text] [Related]
6. New treatment options for erectile dysfunction in patients with diabetes mellitus. Basu A; Ryder RE Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369 [TBL] [Abstract][Full Text] [Related]
8. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994 [TBL] [Abstract][Full Text] [Related]
9. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Gooren LJ; Saad F Asian J Androl; 2006 Jan; 8(1):3-9. PubMed ID: 16372114 [TBL] [Abstract][Full Text] [Related]
10. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. Sommer F; Schulze W World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418 [TBL] [Abstract][Full Text] [Related]
11. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. Archer SL; Gragasin FS; Webster L; Bochinski D; Michelakis ED Drugs Aging; 2005; 22(10):823-44. PubMed ID: 16245957 [TBL] [Abstract][Full Text] [Related]
12. Vardenafil: a review of its use in erectile dysfunction. Keating GM; Scott LJ Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Seftel AD Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I14-19. PubMed ID: 15115191 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats. Wilkes N; White S; Stein P; Bernie J; Rajasekaran M Int J Impot Res; 2004 Apr; 16(2):187-94. PubMed ID: 15073608 [TBL] [Abstract][Full Text] [Related]
19. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. De Young L; Yu D; Freeman D; Brock GB Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. de Tejada IS Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]